Healthcare Dec 28, 2021 11:17 AM (GMT+8) · EqualOcean
Aprinoia therapeutics Inc. (Xinxu, Suzhou Xinxu pharmaceutical parent company) announced on the 28th that it had completed round C financing with a total amount of US $40 million this year. The funds raised by Xinxu were mainly used to promote positron emission tomography of tau protein in Alzheimer's disease (PET) tracer's clinical phase III trial and commercialization in China, and continue to develop drugs suitable for neurodegenerative diseases. In addition, the company will continue to expand its drug discovery and development platform and pipeline, and work with domestic and foreign partners to build a leading and international brain PET clinical imaging alliance. In addition to the continued support of the original shareholders, including KTB network, IMM private equity and Taiwan an biotechnology, this round of financing also welcomes the participation of well-known domestic pharmaceutical enterprises and investment institutions such as Yantai Dongcheng Pharmaceutical Group and Suzhou Yuanfeng Capital Management Co., Ltd. affiliated to Suzhou Industrial Park, so as to deepen the layout of Xinxu in China. The business of Dongcheng pharmaceutical, which is invested in the round C financing, covers the fields of biochemical API, chemical medicine, Chinese patent medicine and nuclear medicine. In the field of nuclear medicine, it has the layout and transportation advantages of the whole industrial chain from diagnostic nuclear medicine to therapeutic nuclear medicine, and can cover the accelerated growth of PET-CT and other testing equipment and the demand for disease diagnosis and treatment in the future.

This text is a result of machine translation.